A GLP-1 receptor agonist studied for appetite regulation and glucose metabolism.
Mimics the GLP-1 hormone released after eating, signaling satiety to the brain and slowing gastric emptying. Also improves insulin sensitivity and reduces glucagon secretion.
Active ingredient in Ozempic and Wegovy. Most studied GLP-1 agonist with extensive clinical trial data. Typically dosed weekly due to very long half-life from fatty acid chain modification.
The C18 fatty acid modification allows albumin binding, dramatically extending its half-life compared to native GLP-1 (which lasts only minutes). This makes weekly dosing sufficient for sustained receptor activation.